BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arendt BM, Allard JP. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required? Am J Gastroenterol. 2011;106:78-80. [PMID: 21212755 DOI: 10.1038/ajg.2010.310] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res 2017;6:40. [PMID: 28503495 DOI: 10.4103/2277-9175.204593] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
2 Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Yano M. High serum carotenoids are associated with lower risk for developing elevated serum alanine aminotransferase among Japanese subjects: the Mikkabi cohort study. Br J Nutr 2016;115:1462-9. [PMID: 26916997 DOI: 10.1017/S0007114516000374] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.6] [Reference Citation Analysis]
3 Sahini N, Borlak J. Recent insights into the molecular pathophysiology of lipid droplet formation in hepatocytes. Prog Lipid Res. 2014;54:86-112. [PMID: 24607340 DOI: 10.1016/j.plipres.2014.02.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 9.0] [Reference Citation Analysis]
4 Mugusi SF, Sando D, Mugusi FM, Hawkins C, Aboud S, Fawzi WW, Sudfeld CR. Risk Factors for Alanine Aminotransferase Elevations in a Prospective Cohort of HIV-Infected Tanzanian Adults Initiating Antiretroviral Therapy. J Int Assoc Provid AIDS Care 2019;18:2325958219884939. [PMID: 31665968 DOI: 10.1177/2325958219884939] [Reference Citation Analysis]
5 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
6 Liu X, Peng Y, Chen S, Sun Q. An observational study on the association between major dietary patterns and non-alcoholic fatty liver disease in Chinese adolescents. Medicine (Baltimore) 2018;97:e0576. [PMID: 29703050 DOI: 10.1097/MD.0000000000010576] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Yang CQ, Shu L, Wang S, Wang JJ, Zhou Y, Xuan YJ, Wang SF. Dietary Patterns Modulate the Risk of Non-Alcoholic Fatty Liver Disease in Chinese Adults. Nutrients 2015;7:4778-91. [PMID: 26083112 DOI: 10.3390/nu7064778] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
8 Mohammed ED, Abdel-Naim AB, Kangpeng J, Jiang R, Wei J, Sun B. The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sci 2021;264:118615. [PMID: 33096115 DOI: 10.1016/j.lfs.2020.118615] [Reference Citation Analysis]
9 Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837-843. [PMID: 25311610 DOI: 10.1016/j.nutres.2014.09.005] [Cited by in Crossref: 167] [Cited by in F6Publishing: 148] [Article Influence: 23.9] [Reference Citation Analysis]
10 Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015;7:204-212. [PMID: 25729475 DOI: 10.4254/wjh.v7.i2.204] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
11 Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2016;17:1937-46. [DOI: 10.1080/14656566.2016.1225727] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
12 McCarthy EM, Rinella ME. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012;112:401-409. [PMID: 22717200 DOI: 10.1016/j.jada.2011.10.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 10.1] [Reference Citation Analysis]
13 Polyzos SA, Kountouras J, Anastasiadis S, Doulberis M, Katsinelos P. Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach? Hepatology 2018;68:389-389. [DOI: 10.1002/hep.29897] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
14 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
15 Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J 2019;95:601-11. [PMID: 31434683 DOI: 10.1136/postgradmedj-2018-136364] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
16 Liu Y, Zhou D, Zhang F, Tu Y, Xia Y, Wang H, Zhou B, Zhang Y, Wu J, Gao X, He Z, Zhai Q. Liver Patt1 deficiency protects male mice from age-associated but not high-fat diet-induced hepatic steatosis. J Lipid Res 2012;53:358-67. [PMID: 22231784 DOI: 10.1194/jlr.M019257] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
17 Godos J, Federico A, Dallio M, Scazzina F. Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. Int J Food Sci Nutr. 2017;68:18-27. [PMID: 27484357 DOI: 10.1080/09637486.2016.1214239] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 9.4] [Reference Citation Analysis]
18 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 121] [Article Influence: 14.7] [Reference Citation Analysis]
19 Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, Yari Z, Hekmatdoost A. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res 2019;33:2118-25. [PMID: 31264313 DOI: 10.1002/ptr.6406] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
20 Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M. Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:616-629.e26. [PMID: 29913275 DOI: 10.1016/j.cgh.2018.06.011] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 14.7] [Reference Citation Analysis]
21 Lee HY, Jun DW, Kim HJ, Oh H, Saeed WK, Ahn H, Cheung RC, Nguyen MH. Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis. Korean J Intern Med 2019;34:296-304. [PMID: 29551054 DOI: 10.3904/kjim.2017.194] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
22 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
24 Wu L, Guo X, Wang W, Medeiros DM, Clarke SL, Lucas EA, Smith BJ, Lin D. Molecular aspects of β, β-carotene-9', 10'-oxygenase 2 in carotenoid metabolism and diseases. Exp Biol Med (Maywood) 2016;241:1879-87. [PMID: 27390265 DOI: 10.1177/1535370216657900] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
25 Lin D, He H, Ji H, Willis J, Willard L, Jiang Y, Medeiros DM, Wark L, Han J, Liu Y, Lu B. Wolfberries potentiate mitophagy and enhance mitochondrial biogenesis leading to prevention of hepatic steatosis in obese mice: the role of AMP-activated protein kinase α2 subunit. Mol Nutr Food Res 2014;58:1005-15. [PMID: 24449471 DOI: 10.1002/mnfr.201300186] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]